Low-density lipoprotein (LDL) apheresis is an approved treatment for (FH) patients who are intolerant or refractory to lipid-lowering medications. The purported benefit of LDL apheresis is its ability to lower the time averaged LDL concentration. The American Society for Apheresis recommends a goal of 40–60 % reduction in time averaged (interval mean) LDL from the pre apheresis level. In this chapter we will discuss the various aspects of this treatment from methodology to outcomes.
KeywordsLDL apheresis (LDLa) Familial hyperlipidemia (FH)
- 3.Kavey RE, Allada V, Daniels SR, et al. Cardiovascular risk reduction in high-risk pediatric patients: a scientific statement from the American heart association expert panel on population and prevention science; the councils on cardiovascular disease in the young, epidemiology and prevention, nutrition, physical activity and metabolism, high blood pressure research, cardiovascular nursing, and the kidney in heart disease; and the interdisciplinary working group on quality of care and outcomes research: endorsed by the American academy of pediatrics. Circulation. 2006;114(24):2710–38.CrossRefPubMedGoogle Scholar
- 7.Immergut, S. U.S. Food and Durg Administration. FDA Approves New Pediatric Use for Liposorber Apheresis System. U.S. Department of helth and Human Services. http://www.fda.gov/medicaldevices/productsandmedicalprocedures/deviceapprovalsandclearances/pmaapprovals/ucm348014.htmAccessed 10 Oct. 2013.
- 8.Parhofer KG, Geiss HC, Schwandt P. Efficacy of different low-density lipoprotein apheresis methods. Ther Aper Dial. 2001;4:382–5.Google Scholar
- 12.Rogers, Roby L., MD, and Laura LW Cooling, MD. “Chapter 21”. In: Bruce C. Mcleod, editors. Apheresis: Priciples and Practice, 2nd ed. Bethesda, MD: AABB; 2010. p. 478–79.Google Scholar